{"id":"timolol-0-5-ophthalmic-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation or discomfort"},{"rate":null,"effect":"Blurred vision"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Systemic beta-blockade effects (bradycardia, bronchospasm in susceptible patients)"}]},"_chembl":{"chemblId":"CHEMBL1200870","moleculeType":"Small molecule","molecularWeight":"432.50"},"_dailymed":{"setId":"9a5aab8f-59b9-4d73-82c4-dc5b8fa8119e","title":"TIMOLOL MALEATE OPHTHALMIC GEL FORMING SOLUTION, 0.25% SOLUTION/ DROPS TIMOLOL MALEATE OPHTHALMIC GEL FORMING SOLUTION, 0.5% SOLUTION/ DROPS [ALEMBIC PHARMACEUTICALS LIMITED]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Timolol blocks beta-1 and beta-2 adrenergic receptors on the ciliary body epithelium, which reduces the rate of aqueous humor secretion. This leads to a decrease in intraocular pressure, making it effective for treating glaucoma and ocular hypertension. The ophthalmic solution formulation allows direct topical application to the eye for local therapeutic effect.","oneSentence":"Timolol is a non-selective beta-adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:12:44.865Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT07495852","phase":"PHASE3","title":"Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant","status":"RECRUITING","sponsor":"Glaukos Corporation","startDate":"2026-02-17","conditions":"Glaucoma","enrollment":510},{"nctId":"NCT07474883","phase":"EARLY_PHASE1","title":"Efficacy of 0.5% Topical Timolol Eye Drops in the Treatment of Post-Inflammatory Erythema Following Acne Vulgaris","status":"NOT_YET_RECRUITING","sponsor":"Pham Ngoc Thach University of Medicine","startDate":"2026-03-09","conditions":"Post Inflammtory Erythema, Acne Vulgaris, Erythema","enrollment":60},{"nctId":"NCT05479123","phase":"PHASE4","title":"Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas","status":"TERMINATED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2022-06-23","conditions":"Infantile Hemangioma","enrollment":52},{"nctId":"NCT04412096","phase":"PHASE4","title":"Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2020-11-23","conditions":"Glaucoma, OHT - Ocular Hypertension","enrollment":59},{"nctId":"NCT07075718","phase":"PHASE2, PHASE3","title":"Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant","status":"RECRUITING","sponsor":"Glaukos Corporation","startDate":"2025-06-12","conditions":"Glaucoma","enrollment":610},{"nctId":"NCT06030193","phase":"PHASE2","title":"Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Qlaris Bio, Inc.","startDate":"2025-08-13","conditions":"Normal Tension Glaucoma (NTG), Low-Tension Glaucoma, Bilateral, Low-Tension Glaucoma, Unspecified Eye","enrollment":36},{"nctId":"NCT07384767","phase":"PHASE2","title":"Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing","status":"NOT_YET_RECRUITING","sponsor":"University of California, Davis","startDate":"2026-06-01","conditions":"Mohs Micrographic Surgery, Excision Margin","enrollment":220},{"nctId":"NCT07168902","phase":"PHASE2","title":"Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension","status":"RECRUITING","sponsor":"Bausch & Lomb Incorporated","startDate":"2025-10-24","conditions":"Glaucoma","enrollment":228},{"nctId":"NCT07218796","phase":"PHASE3","title":"Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)","status":"RECRUITING","sponsor":"SpyGlass Pharma, Inc.","startDate":"2025-10-28","conditions":"Cataract, Glaucoma, Ocular Hypertension","enrollment":400},{"nctId":"NCT07218783","phase":"PHASE3","title":"Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)","status":"RECRUITING","sponsor":"SpyGlass Pharma, Inc.","startDate":"2025-10-15","conditions":"Cataract, Glaucoma, Ocular Hypertension","enrollment":400},{"nctId":"NCT05913232","phase":"PHASE2","title":"Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"D. Western Therapeutics Institute, Inc.","startDate":"2023-08-28","conditions":"Glaucoma Open-Angle Primary, Ocular Hypertension","enrollment":201},{"nctId":"NCT06120842","phase":"PHASE1, PHASE2","title":"Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution","status":"ACTIVE_NOT_RECRUITING","sponsor":"SpyGlass Pharma, Inc.","startDate":"2023-10-13","conditions":"Cataract, Glaucoma, Ocular Hypertension","enrollment":201},{"nctId":"NCT02484716","phase":"PHASE2","title":"Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - (TEMPO)","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2015-06","conditions":"Telangiectasia, Hereditary Hemorrhagic, Osler Rendu Disease","enrollment":58},{"nctId":"NCT06883123","phase":"PHASE4","title":"Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost","status":"RECRUITING","sponsor":"Prairie Eye Center","startDate":"2025-05-14","conditions":"Open Angle Glaucoma","enrollment":70},{"nctId":"NCT04149899","phase":"PHASE1, PHASE2","title":"Safety and IOP-Lowering Effects of WB007","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2019-11-14","conditions":"Glaucoma, Primary Open Angle, Ocular Hypertension","enrollment":77},{"nctId":"NCT06813807","phase":"PHASE1","title":"A Comparative Study of the Pharmacokinetic Profiles of Timolol Maleate Ophthalmic Gel With Timolol Maleate Gel","status":"COMPLETED","sponsor":"Auson Pharmaceuticals Inc.","startDate":"2024-06-15","conditions":"Healthy Subjects","enrollment":18},{"nctId":"NCT04857827","phase":"PHASE2","title":"A Study to Evaluate Safety and Tolerability of QLS-101 in NTG","status":"COMPLETED","sponsor":"Qlaris Bio, Inc.","startDate":"2021-09-15","conditions":"Normal Tension Glaucoma (NTG)","enrollment":30},{"nctId":"NCT04830397","phase":"PHASE2","title":"Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).","status":"COMPLETED","sponsor":"Qlaris Bio, Inc.","startDate":"2021-03-31","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":84},{"nctId":"NCT06761313","phase":"PHASE4","title":"Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Federal University of São Paulo","startDate":"2021-03-01","conditions":"Glaucoma, Quality of Life (QOL)","enrollment":40},{"nctId":"NCT03519386","phase":"PHASE3","title":"Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%","status":"COMPLETED","sponsor":"Glaukos Corporation","startDate":"2018-07-26","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":590},{"nctId":"NCT03868124","phase":"PHASE3","title":"Clinical Study Comparing Two Models of a Travoprost Intraocular Implant","status":"COMPLETED","sponsor":"Glaukos Corporation","startDate":"2018-09-17","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":560},{"nctId":"NCT06643416","phase":"PHASE3","title":"Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia","status":"RECRUITING","sponsor":"Queen Mary Hospital, Hong Kong","startDate":"2024-10-09","conditions":"Paronychia, EGFR-TKI, ALK-TKI","enrollment":40},{"nctId":"NCT05503901","phase":"PHASE3","title":"A Long Term Study of STN1012600 in Subjects With Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2022-08-08","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":131},{"nctId":"NCT04910100","phase":"PHASE2","title":"Nebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution to Treat Glaucoma/Ocular Hypertension","status":"COMPLETED","sponsor":"Betaliq, Inc.","startDate":"2021-04-15","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":226},{"nctId":"NCT06140186","phase":"PHASE3","title":"Efficacy and Safety of Timolol for TKI Induced Paronychia","status":"UNKNOWN","sponsor":"Queen Mary Hospital, Hong Kong","startDate":"2023-04-01","conditions":"Paronychia","enrollment":40},{"nctId":"NCT04702789","phase":"PHASE4","title":"Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension.","status":"TERMINATED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2021-10-19","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":28},{"nctId":"NCT06152861","phase":"PHASE2","title":"Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension","status":"UNKNOWN","sponsor":"Glaukos Corporation","startDate":"2023-11-15","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":250},{"nctId":"NCT01873131","phase":"NA","title":"A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2011-02","conditions":"Hemangioma","enrollment":126},{"nctId":"NCT02754596","phase":"PHASE2","title":"Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution","status":"COMPLETED","sponsor":"Glaukos Corporation","startDate":"2016-03-29","conditions":"Glaucoma Open-angle","enrollment":154},{"nctId":"NCT01685398","phase":"PHASE3","title":"Topical Timolol for Superficial Infantile Hemangioma","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2012-09","conditions":"Hemangioma","enrollment":48},{"nctId":"NCT03691649","phase":"PHASE3","title":"A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2018-09-14","conditions":"Glaucoma and Ocular Hypertension","enrollment":426},{"nctId":"NCT01699464","phase":"PHASE2","title":"A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2012-10","conditions":"Ocular Hypertension, Open-angle Glaucoma","enrollment":211},{"nctId":"NCT03691662","phase":"PHASE3","title":"A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2018-09-27","conditions":"Glaucoma and Ocular Hypertension","enrollment":417},{"nctId":"NCT04742283","phase":"PHASE2","title":"Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2020-12-17","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":323},{"nctId":"NCT05165082","phase":"NA","title":"The Efficacy of Topical Timolol Combined With Cryotherapy in EGFR Inhibitors-induced Paronychia - a Double-blinded, Intrapatient Left-to-right Controlled Study","status":"COMPLETED","sponsor":"Taipei Medical University WanFang Hospital","startDate":"2021-12-21","conditions":"Paronychia, Epidermal Growth Factor Receptor Inhibitor","enrollment":8},{"nctId":"NCT05181046","phase":"NA","title":"Evaluation of Nanodropper-mediated Microdrops vs. Standard Drops of 0.5% Timolol Maleate in Glaucoma Patients","status":"COMPLETED","sponsor":"Nanodropper, Inc.","startDate":"2021-11-06","conditions":"Glaucoma, Glaucoma, Open-Angle, Glaucoma, Primary Open Angle","enrollment":420},{"nctId":"NCT04296916","phase":"NA","title":"Effect of Lowering IOP in Glaucoma Suspects With HM","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-04-17","conditions":"Glaucoma, Suspect, High Myopia","enrollment":264},{"nctId":"NCT03284853","phase":"PHASE3","title":"Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2017-09-05","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":436},{"nctId":"NCT03648229","phase":"PHASE4","title":"African Glaucoma Laser Trial","status":"WITHDRAWN","sponsor":"West Virginia University","startDate":"2019-09-01","conditions":"Open-angle Glaucoma","enrollment":""},{"nctId":"NCT00856622","phase":"PHASE3","title":"A Study Demonstrating The Effect Of Latanoprost In Combination With Timolol, Latanoprost Alone And Timolol Alone On Eye Pressure In Open Angle Glaucoma Or Ocular Hypertension In Patients","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"1997-08","conditions":"Ocular Hypertension, Glaucoma, Open-angle Glaucoma","enrollment":436},{"nctId":"NCT00716859","phase":"PHASE3","title":"A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2008-07","conditions":"Glaucoma","enrollment":139},{"nctId":"NCT02250612","phase":"PHASE2","title":"SYL040012, Treatment for Open Angle Glaucoma","status":"COMPLETED","sponsor":"Sylentis, S.A.","startDate":"2014-10","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":184},{"nctId":"NCT03323164","phase":"PHASE4","title":"Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study","status":"COMPLETED","sponsor":"Wills Eye","startDate":"2017-07-10","conditions":"Glaucoma; Drugs, Normal Tension Glaucoma, Primary Open-angle Glaucoma","enrollment":35},{"nctId":"NCT02358369","phase":"PHASE2","title":"Dose-Ranging Study of the Bimatoprost Ocular Insert","status":"COMPLETED","sponsor":"ForSight Vision5, Inc.","startDate":"2015-01-19","conditions":"Primary Open-Angle Glaucoma, Ocular Hypertension","enrollment":156},{"nctId":"NCT04288700","phase":"PHASE4","title":"Evaluation of the Efficacy of Captopril Versus Propranolol and Timolol as a Treatment of Infantile Capillary Hemangioma","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2019-10-01","conditions":"Infantile Hemangioma","enrollment":100},{"nctId":"NCT03966365","phase":"PHASE1","title":"Safety and Tolerability of the Preservative-free Ophthalmic Solution PRO-122 Compared With Krytantek Ofteno®","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2019-05-02","conditions":"Glaucoma","enrollment":24},{"nctId":"NCT01257698","phase":"NA","title":"Effect of Topical Aqueous Suppressants on Intraocular Gas Duration Following Pars Plana Vitrectomy","status":"COMPLETED","sponsor":"Mid Atlantic Retina","startDate":"2010-02","conditions":"Macular Hole, Retinal Detachment","enrollment":21},{"nctId":"NCT03836664","phase":"PHASE2","title":"A Randomized Study Evaluating the Efficacy and Safety of Timolol Ophthalmic Solution as an Acute Treatment of Migraine","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2017-02-27","conditions":"Migraine","enrollment":25},{"nctId":"NCT03966560","phase":"PHASE4","title":"Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma","status":"COMPLETED","sponsor":"Afyon Kocatepe University Hospital","startDate":"2014-01","conditions":"Glaucoma, Open-Angle","enrollment":96},{"nctId":"NCT02730871","phase":"PHASE4","title":"Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2016-06-24","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":173},{"nctId":"NCT01170884","phase":"PHASE4","title":"Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-12","conditions":"Glaucoma, Ocular Hypertension","enrollment":121},{"nctId":"NCT00811850","phase":"PHASE4","title":"Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow","status":"COMPLETED","sponsor":"Allergan","startDate":"2008-12","conditions":"Glaucoma","enrollment":15},{"nctId":"NCT01243567","phase":"PHASE4","title":"Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost in Patients With Open-Angle Glaucoma Who Have Never Been Treated","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-06-01","conditions":"Glaucoma, Open-Angle","enrollment":81},{"nctId":"NCT01068964","phase":"NA","title":"Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-02-01","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":235},{"nctId":"NCT01533376","phase":"PHASE1","title":"Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol","status":"TERMINATED","sponsor":"Wills Eye","startDate":"2012-02","conditions":"Sturge Weber Syndrome, Port-wine Mark","enrollment":3},{"nctId":"NCT01749930","phase":"PHASE3","title":"Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2013-01","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":420},{"nctId":"NCT01749904","phase":"PHASE3","title":"Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2013-01-31","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":420},{"nctId":"NCT01254604","phase":"PHASE3","title":"Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-12-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":190},{"nctId":"NCT01707381","phase":"PHASE2","title":"BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2012-11","conditions":"Ocular Hypertension, Open Angle Glaucoma","enrollment":25},{"nctId":"NCT02571712","phase":"PHASE4","title":"Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2015-11-10","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":750},{"nctId":"NCT01927406","phase":"PHASE4","title":"The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2014-06","conditions":"Thyroid Eye Disease, Ocular Hypertension, Glaucoma","enrollment":""},{"nctId":"NCT01915940","phase":"PHASE2","title":"Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"ForSight Vision5, Inc.","startDate":"2013-10-23","conditions":"Primary Open-Angle Glaucoma, Ocular Hypertension","enrollment":169},{"nctId":"NCT02207491","phase":"PHASE3","title":"Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2014-07","conditions":"Ocular Hypertension, Open-angle Glaucoma","enrollment":411},{"nctId":"NCT02558374","phase":"PHASE3","title":"Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2015-09","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":708},{"nctId":"NCT02246764","phase":"PHASE3","title":"Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2014-09","conditions":"Ocular Hypertension, Glaucoma","enrollment":93},{"nctId":"NCT02207621","phase":"PHASE3","title":"Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2014-07","conditions":"Ocular Hypertension, Open-angle Glaucoma","enrollment":756},{"nctId":"NCT02697318","phase":"EARLY_PHASE1","title":"Evaluation of a New Method for Instilling Eye Drops","status":"COMPLETED","sponsor":"University of Waterloo","startDate":"2016-05","conditions":"Ophthalmic Solutions, Glaucoma","enrollment":30},{"nctId":"NCT01535768","phase":"PHASE4","title":"Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves","status":"UNKNOWN","sponsor":"Credit Valley EyeCare","startDate":"2012-02","conditions":"Glaucoma","enrollment":150},{"nctId":"NCT02278614","phase":"PHASE3","title":"Efficacy and Safety Assessment of T2347 Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients","status":"COMPLETED","sponsor":"Laboratoires Thea","startDate":"2014-12","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":242},{"nctId":"NCT01217606","phase":"PHASE3","title":"Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-01","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":185},{"nctId":"NCT02312544","phase":"PHASE2","title":"Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2014-11","conditions":"Glaucoma, Ocular Hypertension","enrollment":72},{"nctId":"NCT01845038","phase":"PHASE1","title":"Multi-Arm Feasibility Study Evaluating OTX-TP Compared to Timolol in Treatment of Subjects With Open Angle Glaucoma","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2013-04","conditions":"Glaucoma","enrollment":41},{"nctId":"NCT02325518","phase":"PHASE4","title":"Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution","status":"COMPLETED","sponsor":"Alcon, a Novartis Company","startDate":"2014-12","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":218},{"nctId":"NCT02565173","phase":"PHASE3","title":"Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma","status":"COMPLETED","sponsor":"Inotek Pharmaceuticals Corporation","startDate":"2015-09","conditions":"Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)","enrollment":303},{"nctId":"NCT00759239","phase":"PHASE4","title":"Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-09","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":36},{"nctId":"NCT01230736","phase":"PHASE4","title":"Safety and Efficacy of Changing to DuoTrav From Prior Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-10","conditions":"Glaucoma","enrollment":105},{"nctId":"NCT00519753","phase":"PHASE4","title":"Success of Transitioning Uncontrolled Glaucoma Patients From Prior Mono or Adjunctive Therapy to DuoTrav","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2007-08","conditions":"Glaucoma","enrollment":522},{"nctId":"NCT00061542","phase":"PHASE3","title":"Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2003-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":105},{"nctId":"NCT01434849","phase":"PHASE1","title":"Timolol for the Prevention of Proliferation of Infantile Hemangioma (TiPPIH Trial)","status":"TERMINATED","sponsor":"Alice K. Gong","startDate":"2012-07","conditions":"Infantile Hemangioma, Very Low Birth Weight Infants","enrollment":26},{"nctId":"NCT02003391","phase":"PHASE4","title":"Efficacy of Travoprost/Timolol for Uncontrolled Intraocular Pressure","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-12","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":157},{"nctId":"NCT02097719","phase":"PHASE4","title":"Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-05","conditions":"Glaucoma, Ocular Hypertension","enrollment":100},{"nctId":"NCT01881126","phase":"PHASE4","title":"An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-06","conditions":"Glaucoma, Ocular Hypertension","enrollment":93},{"nctId":"NCT02214680","phase":"PHASE2","title":"The Effect of Topical Treatment With Combigan Compared to Timolol and Brimonidine on Pupil Diameter","status":"UNKNOWN","sponsor":"Carmel Medical Center","startDate":"2015-10","conditions":"Healthy","enrollment":25},{"nctId":"NCT01215786","phase":"PHASE1","title":"Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-10","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":50},{"nctId":"NCT01652664","phase":"PHASE3","title":"Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2012-09","conditions":"Pediatric Glaucoma, Elevated IOP in Pediatric Patients, Ocular Hypertension in Pediatric Patients","enrollment":184},{"nctId":"NCT01342094","phase":"PHASE3","title":"DE-111 Against Timolol Ophthalmic Solution 0.5%","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2011-05","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":166},{"nctId":"NCT01342081","phase":"PHASE3","title":"DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2011-05","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":489},{"nctId":"NCT00804648","phase":"PHASE4","title":"Patient Satisfaction With Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Vistakon Pharmaceuticals","startDate":"2008-11","conditions":"Glaucoma, Open Angle, Ocular Hypertension","enrollment":30},{"nctId":"NCT00823043","phase":"","title":"A Comfort Survey of Open-angle Glaucoma or Ocular Hypertension Patients Treated With 2 Drugs","status":"COMPLETED","sponsor":"Vistakon Pharmaceuticals","startDate":"2009-01","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":103},{"nctId":"NCT01514721","phase":"PHASE4","title":"Efficacy of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination) From Prior Therapy","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2012-06","conditions":"Glaucoma","enrollment":37},{"nctId":"NCT01241240","phase":"PHASE3","title":"Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-03","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":192},{"nctId":"NCT01547598","phase":"PHASE4","title":"Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) Reduction","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-12","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":135},{"nctId":"NCT00465803","phase":"PHASE3","title":"A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2007-03","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":81},{"nctId":"NCT00760539","phase":"PHASE3","title":"Safety and Efficacy of Travoprost/Timolol BAC-free","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-06","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":87},{"nctId":"NCT00672997","phase":"PHASE3","title":"A Phase III Study of Travoprost/Timolol Combination in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-05","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":301},{"nctId":"NCT00330577","phase":"PHASE4","title":"24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2006-04","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":30},{"nctId":"NCT01302249","phase":"PHASE2","title":"AR-12286 in Combination With Latanoprost","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2011-02","conditions":"Glaucoma, Ocular Hypertension","enrollment":66},{"nctId":"NCT01357616","phase":"PHASE3","title":"Fixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-11","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":328},{"nctId":"NCT01340014","phase":"PHASE4","title":"Patient Preference Comparison of AZARGA Versus COSOPT","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-09","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":112},{"nctId":"NCT01327599","phase":"PHASE4","title":"Efficacy of Changing to DUOTRAV® From Prior Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-08","conditions":"Open-Angle Glaucoma, Ocular Hypertension, Pigment Dispersion Glaucoma","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":33,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["timoptic","Timoptol","TIMOLOL"],"phase":"marketed","status":"active","brandName":"Timolol 0.5% Ophthalmic Solution","genericName":"Timolol 0.5% Ophthalmic Solution","companyName":"University of California, Davis","companyId":"university-of-california-davis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Timolol is a non-selective beta-adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye. Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}